Anna Becker studied Clinical Psychology and Neuroscience at the University of Basel. As a student assistant, she helped investigating the neuro-cognitive underpinnings of judgment and decision processes in people with schizophrenia as well as dopaminergic influences on (EEG) resting-state connectivity in people with psychotic disorders.Since 2020 she has been a PhD Candidate in the psychopharmacology research group of Prof. Matthias Liechti at the University Hospital Basel where she investigates the role of 5-HT2A receptor down-regulation and antagonism in the acute effects of psilocybin and LSD.In this function, she has accompanied over 100 psychedelic experiences from healthy test subjects as well as people with depression. She is interested in the basic physiological processes of psychoactive substances as well as their psychotherapeutic applications. Since 2021 she started an additional training to become a psychodynamic psychotherapist. The team also characterizes the pharmacology of the constantly emerging novel psychoactive substances (designer drugs) using in vitro methods. In experimental clinical studies, Matthias Liechti investigates the clinical pharmacology of psychostimulants, MDMA, LSD, psilocybin and mescaline. The team also conducts Pharmaco-fMRI studies in collaboration with the Department of Psychiatry. Further, the group conducts phase-2 studies with LSD in patients with cluster headaches, anxiety disorder and major depression in collaboration with the respective disease specialists.